FORUS Therapeutics is thrilled to welcome Lisa Kolomaya as Therapeutic Area Manager, Hematology/Oncology, AB/SK. Lisa is a results-driven life sciences professional with extensive expertise in both oncology and hematology. Guided by a strategic mindset and passion for...

FORUS Therapeutics is thrilled to welcome Erin Webb as Therapeutic Area Manager, Hematology/Oncology, SW ON. Erin began her career as a physician assistant in the US, caring for patients with both benign and malignant hematologic conditions as well as managing...

FORUS Therapeutics a le plaisir d’annoncer que BESREMiMD (ropeginterféron alfa-2b-njft) autorisé aux É.-U. est maintenant disponible au Canada, par l’entremise d’une importation exceptionnelle. Veuillez noter que l’ingrédient actif de BESREMiMD, le ropeginterféron...

FORUS Therapeutics Inc. et PharmaEssentia Corporation ont conclu un accord de licence exclusif pour l’enregistrement et la commercialisation de BESREMi® (ropeginterféron alfa-2b) pour le traitement de la polycythémie vraie (PV) au Canada. Selon les termes de l’accord,...

FORUS Therapeutics is thrilled to welcome Karen Winkworth as Therapeutic Area Manager, Hematology/Oncology, GTA. Karen brings with her a proven track record of delivering superior value across therapeutic areas - including over 15 years in hematology and oncology....

FORUS Therapeutics is delighted to welcome Chris Mitton as Therapeutic Area Manager, Hematology/Oncology, Atlantic Canada. Chris joins FORUS with over 30 years experience as a pharmaceutical professional with extensive expertise across various therapeutic areas,...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Nova Scotia as of October 1st. Please see the following link for full funding criteria: Nova Scotia Pharmacare News Bulletins Pharmacy Edition (novascotia.ca) We are excited...

In a remarkable decision posted earlier this month, INESSS stands alone in failing to recognize the therapeutic value of XPOVIO. This despite Health Canada approval, a positive CADTH decision, Quebec clinician and patient support and positive funding recommendations...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in PEI as of April 23rd. Please see the following links for full funding criteria:  PEI Pharmacare Bulletin – Pharmacist Bulletin – April 09, 2024 We are excited about these...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Ontario, Newfoundland and Labrador, and New Brunswick. Please see the following links for full funding criteria: Ontario: Exceptional Access Program | ontario.ca Newfoundland...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in British Columbia as of October 1, 2023. Further details on the criteria can be found here, under the MYBSD protocol: Lymphoma & Myeloma (bccancer.bc.ca) We are excited...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Saskatchewan as of September 1st. Please see the following link for full funding criteria: Drug Formulary (saskcancer.ca). We are excited about this important milestone for...